Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI

Liu, Li-Heng; Zhou, Guofeng; Lv, Han; Wang, Zhenchang; Rao, Sheng-Xiang; Zeng, Mengsu

doi:10.1007/s00330-020-07647-2

Cited by 13 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with previous studies, 24 of 49 lesions showed pathological chemotherapy response (16,17,26). Inter-lesion pretreatment whole area ADC was heterogeneous, with a range of 0.731–1.57 × 10 −3 mm 2 /s, which is similar to the findings of Boraschi et al (25), who found pretreatment ADC to be in the range of 0.73–1.51 × 10 −3 mm 2 /s in a study of 24 patients with CRLMs undergoing diffusion-weighted 3-T MRI.…”

Section: Discussionsupporting

confidence: 92%

“…To overcome this problem, it has been suggested that the change between pre- and post-treatment ADC measured using the same MRI scanner should be used rather than single absolute ADC measurements (24). Only a few previous studies have investigated the association between change in CRLM ADCs after preoperative chemotherapy and pathological chemotherapy response (25,26).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in apparent diffusion coefficient and pathological response in colorectal liver metastases after preoperative chemotherapy

et al. 2022

View full text Add to dashboard Cite

Background The pathological response to preoperative chemotherapy of colorectal liver metastases (CRLMs) is predictive of long-term prognosis after liver resection. Accurate preoperative assessment of chemotherapy response could enable treatment optimization. Purpose To investigate whether changes in lesion-apparent diffusion coefficient (ADC) measured with diffusion-weighted magnetic resonance imaging (MRI) can be used to assess pathological treatment response in patients with CRLMs undergoing preoperative chemotherapy. Material and Methods Patients who underwent liver resection for CRLMs after preoperative chemotherapy between January 2011 and December 2019 were retrospectively included if they had undergone MRI before and after preoperative chemotherapy on the same 1.5-T MRI scanner with diffusion-weighted imaging with b-values 50, 400, and 800 s/mm2. The pathological chemotherapy response was assessed using the tumor regression grade (TRG) by AJCC/CAP. Lesions were divided into two groups: pathological responding (TRG 0–2) and non-responding (TRG 3). The change in lesion ADC after preoperative chemotherapy was compared between responding and non-responding lesions. Results A total of 27 patients with 49 CRLMs were included, and 24/49 lesions showed a pathological chemotherapy response. After chemotherapy, ADC increased in both pathological responding (pretreatment ADC: 1.26 [95% confidence interval (CI)=1.06–1.37] vs. post-treatment ADC: 1.33 [95% CI=1.13–1.56] × 10−3 mm2/s; P = 0.026) and non-responding lesions (1.12 [95% CI=0.980–1.21] vs. 1.20 [95% CI=1.09–1.43] × 10−3 mm2/s; P = 0.018). There was no difference in median relative difference in ADC after chemotherapy between pathological responding and non-responding lesions (15.8 [95% CI=1.42–26.3] vs. 7.17 [95% CI=−4.31 to 31.2]%; P = 0.795). Conclusion Changes in CRLM ADCs did not differ between pathological responding and non-responding lesions.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Changes in apparent diffusion coefficient and pathological response in colorectal liver metastases after preoperative chemotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A study [ 16 ] showed that gemcitabine combined with cisplatin significantly prolonged the patients' survival with high therapeutic efficiency in the treatment of esophageal cancer. Bevacizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that inhibits vascular endothelial growth factor, affects vascular permeability and proliferation, and involves in the migration and survival of endothelial cells, which serves to inhibit tumor angiogenesis, growth, and metastasis, and accounts for its extensive use in various types of metastatic cancers [ 17 – 19 ]. In this study, the total treatment efficiency in the study group was 86%, which was significantly higher than that of 66% in the control group ( P < 0.05), indicating a superior treatment efficiency of triple therapy to that of therapy of gemcitabine combined with cisplatin.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Zhao

Cai

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of bevacizumab and gemcitabine in combination with cisplatin in the treatment of esophageal cancer and the effect on the incidence of adverse reactions. Methods. A total of 100 esophageal cancer patients admitted to our hospital from March 2019 to March 2021 were identified as research subjects and randomized into the control group and the study group, with 50 cases in each group. The control group was treated with gemcitabine combined with cisplatin, and the study group was treated with the triple therapy of bevacizumab, gemcitabine, and cisplatin. The treatment efficiency and the incidence of adverse reactions were compared between the two groups of patients. Results. The total treatment efficiency in the study group was 86%, which was significantly higher than that of 66% in the control group ( P < 0.05 ). After treatment, the levels of vascular endothelial growth factor (VEGF), Cyfra21-1, and C-met were reduced in both groups, with significantly lower levels in the study group than in the control group ( P < 0.05 ). The incidence of all CTCAE, ototoxicity, and nephrotoxicity was comparable between the two groups ( P > 0.05 ). The survival rates of patients in the study group were 88% and 54% at 1 and 2 years after treatment, which were significantly higher than that of 68% and 32% in the control group ( P < 0.05 ). Conclusion. The clinical efficiency of bevacizumab and gemcitabine combined with cisplatin in the treatment of esophageal cancer is remarkable, which improves the survival of patients, and is worthy of clinical promotion and application.

show abstract

“…MRI is the imaging technique of choice in the assessment of focal liver lesions [67][68][69][70][71][72][73], particulary, in the diagnostic phase and during the follow up after treatment in HCC patients [74][75][76][77][78][79][80][81][82]. In the following section we will focus on several particular MRI features in the workup of HCC patients: morfological assessment, dynamic contrast enhancement (DCE)-MRI, diffusionweighted imaging (DWI), Bold sequences.…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma

Granata

Grassi

Fusco³

et al. 2021

Infect Agents Cancer

View full text Add to dashboard Cite

This article provides an overview of diagnostic evaluation and ablation treatment assessment in Hepatocellular Carcinoma (HCC). Only studies, in the English language from January 2010 to January 202, evaluating the diagnostic tools and assessment of ablative therapies in HCC patients were included. We found 173 clinical studies that satisfied the inclusion criteria.HCC may be noninvasively diagnosed by imaging findings. Multiphase contrast-enhanced imaging is necessary to assess HCC. Intravenous extracellular contrast agents are used for CT, while the agents used for MRI may be extracellular or hepatobiliary. Both gadoxetate disodium and gadobenate dimeglumine may be used in hepatobiliary phase imaging. For treatment-naive patients undergoing CT, unenhanced imaging is optional; however, it is required in the post treatment setting for CT and all MRI studies. Late arterial phase is strongly preferred over early arterial phase. The choice of modality (CT, US/CEUS or MRI) and MRI contrast agent (extracelllar or hepatobiliary) depends on patient, institutional, and regional factors. MRI allows to link morfological and functional data in the HCC evaluation. Also, Radiomics is an emerging field in the assessment of HCC patients.Postablation imaging is necessary to assess the treatment results, to monitor evolution of the ablated tissue over time, and to evaluate for complications. Post- thermal treatments, imaging should be performed at regularly scheduled intervals to assess treatment response and to evaluate for new lesions and potential complications.

show abstract

Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI

Cited by 13 publications

References 30 publications

Changes in apparent diffusion coefficient and pathological response in colorectal liver metastases after preoperative chemotherapy

Changes in apparent diffusion coefficient and pathological response in colorectal liver metastases after preoperative chemotherapy

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma

Contact Info

Product

Resources

About